



## **UNITY Biotechnology, Inc. to Announce Second Quarter 2018 Financial Results**

July 31, 2018

SAN FRANCISCO, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the second quarter ended June 30, 2018, on Thursday, August 9, 2018, after NASDAQ market close.

UNITY will not conduct a conference call in conjunction with the financial results press release.

### **About UNITY Biotechnology**

UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at [www.unitybiotechnology.com](http://www.unitybiotechnology.com) or follow us on [Twitter](#).

### Investors

Endurance Advisors Elizabeth Broder [ebroder@enduranceadvisors.com](mailto:ebroder@enduranceadvisors.com)

### Media

Canale Communications Jason Spark

1-619-849-6005

[jason@canalecomm.com](mailto:jason@canalecomm.com)

 [Primary Logo](#)

Source: Unity Biotechnology, Inc.